Johnson & Johnson’s Janssen Pharmaceutical made a strategic call to halt development of pimodivir, an antiviral treatment for influenza A.
Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test to differentiate between Covid-19 and common winter diseases.
The United States surpassed 170,000 coronavirus deaths, according to a Reuters tally, as health officials express concerns over Covid-19 complicating the fall flu season.
Polls show that up to 50 percent of Americans are unwilling to be vaccinated against COVID-19 once a vaccine becomes available.
Substantial activity from the novel coronavirus combined with a major flu season this fall could place a tremendous burden on the healthcare system, a top U.S. health official said.
San Diego-based Ansun Pharmaceuticals used the company’s influenza research data to dive into attempts to develop a treatment for COVID-19 with an investigational nebulized enzyme asset as a potential treatment for severely infected patients.
The H3N2 flu originated in Hong Kong in July 1968, appeared in the United States during that September, and is still circulating as a type of Influenza A. Globally, about one million people died until the outbreak faded during the winter of 1969-70.
With all the similarities, there are several significant differences between the COVID-19 and the Spanish Flu of 1918 pandemics.
The U.S. Food and Drug Administration accepted a New Drug Application and two supplemental NDAs for Genentech’s Xofluza (baloxavir marboxil).
Italian researchers are looking at whether a higher than usual number of cases of severe pneumonia and flu in Lombardy in the last quarter of 2019 may be a signal that the new coronavirus might have spread beyond China earlier than previously thought.